Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurogene Inc. - Common Stock (NQ:NGNE)

22.54 +0.08 (+0.36%)
Streaming Delayed Price Updated: 9:40 AM EST, Nov 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurogene Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome
From Neurogene Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene to Participate in Upcoming Conferences
From Neurogene Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Crude Oil Rises Sharply; US Homebuilder Sentiment Surges In November ↗
 
Via Benzinga
News headline image
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Dow Falls 100 Points; Brady Posts Upbeat Results ↗
 
Via Benzinga
Topics Stocks
News headline image
Neurogene — Down 36% — Extends Losses After Side Effect Derails Its Rett Syndrome Drug ↗
The company is now scrapping a high dose of its Rett syndrome drug after a patient experienced a serious side effect. 
Via Investor's Business Daily
News headline image
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
From Neurogene Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 15, 2024 ↗
 
Via Benzinga
News headline image
Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"
Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks. 
Via MarketBeat
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Dow Dips Over 200 Points; Home Depot Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial ↗
Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing improved safety and efficacy. 
Via Benzinga
News headline image
Top 1% Biotech Neurogene Crashes, Wiping Out A Run, On A Serious Side Effect ↗
Neurogene tested its gene therapy in female patients with Rett syndrome. 
Via Investor's Business Daily
News headline image
Why Grab Holdings Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
From Neurogene Inc.
Via Business Wire
News headline image
S&P 500 Edges Lower; Yum China Earnings Top Views ↗
 
Via Benzinga
Topics Stocks
News headline image
Crude Oil Gains 3%; Constellation Energy Shares Tumble After Q3 Results ↗
 
Via Benzinga
News headline image
Integra LifeSciences Posts Upbeat Results, Joins Air Transport Services, Freshpet, Yum China And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Neurogene Announces Oversubscribed $200 Million Private Placement
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
From Neurogene
Via Business Wire
News headline image
NGNE Stock Earnings: Neurogene Misses EPS for Q2 2024 ↗
NGNE stock results show that Neurogene missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.